In support of the mutator phenotype hypothesis [67], mutations in MLL3 seem to be acquired at a later stage of tumour development (passenger mutations) and are not initiators of tumour formation as opposed to driver mutations like KRAS G12V/D [68]. The gene discussed is KRAS; the disease is neoplasm.